All In Biotech

Drugs by condition

Drugs approved for endometrial cancer

Brand-name prescription drugs and biologics whose FDA label lists endometrial cancer as an approved use. Matched on the label phrases: "endometrial".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

9

Still marketed, NDA or BLA

Drug classes

7

Novel drugs

7

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for endometrial cancer.

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • Jemperli (Dostarlimab-Gxly) · Glaxosmithkline NovelBreakthrough therapyAccelerated approvalPriority reviewApr 22, 2021
  • Imfinzi (Durvalumab) · Astrazeneca Uk LTD NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMay 1, 2017
  • Lenvima (Lenvatinib Mesylate) · Eisai INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanFeb 13, 2015
  • Keytruda (Pembrolizumab) · Merck Sharp Dohme NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanSep 4, 2014

All approved drugs for endometrial cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 19 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Programmed Death Receptor-1 Blocking Antibody (2)

  • Jemperli Dostarlimab-Gxly · Glaxosmithkline · 2021
  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014

Endoglycosidase (1)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025

Programmed Death Ligand-1 Blocker (1)

  • Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017

Kinase Inhibitor (1)

  • Lenvima Lenvatinib Mesylate · Eisai INC · 2015

Gonadotropin (1)

  • Ovidrel Choriogonadotropin Alfa · Emd Serono · 2000

Progesterone (1)

Class not listed in FDA's data (2)

  • Zoladex Goserelin Acetate · Tersera · 1989
  • Provera Medroxyprogesterone Acetate · Pfizer · 1959

Drugs in development for endometrial cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • Rina-SPRO1184, GEN1184Phase 39 trials

    Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer

  • Mocertatug rezetecanMo-RezPhase 36 trials

    GSK · Ovarian Neoplasms, Neoplasms, Endometrial, Tumours, Gynecological

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials

    DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer

  • AL8326Phase 34 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials

    AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma

  • HB0025Phase 34 trials

    Shanghai Huaota Biopharmaceutical Co., Ltd. · First-line pMMR Endometrial Cancer, Non Squamous Non-small Cell Lung Cancer, TNBC

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • HS-20089Phase 33 trials

    Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer

  • EG-007Phase 32 trials

    Evergreen Therapeutics, Inc. · Advanced Endometrial Cancer

  • TQB2450Phase 32 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Endometrial Cancer, Non Small Cell Lung Cancer

  • TR115Phase 32 trials

    Tarapeutics Science Inc. · Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent

  • Olaparib phasePhase 31 trial

    AstraZeneca · Advanced or Recurrent Endometrial Cancer

More on endometrial cancer: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.